Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Lilly signs real-world digital diabetes deal with Livongo

Will work with the US consumer digital health firm on research collaboration

Eli Lilly and Company

Lilly is partnering with a US consumer digital health company for real-world research that it hopes will allow patients with diabetes to better understand their condition.

The pharma firm will work with Livongo to develop predictive and prescriptive recommendations for patients through a combination of real-world studies and claims data.

Livongo combines consumer health tech, personalised recommendations and real-time support to help people manage chronic conditions, starting with diabetes.

The companies will focus on remote self-management education and support, the drivers underlying healthy behaviour and how patients can remain actively involved in their health.

Sherry Martin, vice president of medical affairs at Lilly Diabetes, said: "Collaborating with Livongo is an important step in our research efforts. We hope that our combined expertise will play a key role in empowering people with diabetes to better manage their condition."

Livongo, which wants to redesign chronic disease management, counts four of the seven largest US health plans and over 200 employers among its clients.

Chief medical officer Jennifer Schneider said the company’s work with Lilly would have a direct impact on the lives of Livongo members.

She added: “Livongo uses reinforcement learning to create customised and actionable insights that guide people to better manage their diabetes. The knowledge we gain from these studies will be incorporated into our diabetes management platform to help drive better health outcomes for our members."

Lilly said it planned to publish the results of their collaborative research studies to further advance diabetes care.

The company’s deal follow in the wake of last month’s agreement with US software and analytics firm Rimidi to boost an in-house diabetes solution it is working on.

10th January 2018

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics